Drug intelligence / Profile preview

KH607

Development stage: Phase 3
Lead developer: Chengdu Kanghong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KH607 is a small molecule drug candidate that acts as a positive allosteric modulator of the GABAA receptor. It is being developed for central nervous system indications, with its primary mechanism involving enhancement of GABAA receptor activity. The drug was initially developed by Chengdu Kanghong Pharmaceutical Group and is currently in Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers. The oral formulation is being tested in both single ascending dose (SAD) and multiple ascending dose (MAD) studies[1][2][3].

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on KH607.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH607.

Explore the full profile